Stock AnalizTravere Therapeutics, Inc. TVTX
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Travere Therapeutics, Inc. (TVTX) is a healthcare company listed in the US with a market value of about $4.9B. In the twelve months to September 30, 2026 it had revenue of $651M and net income of -$122M, a net margin of -18.7%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 20% a year, a 5-year average ROIC of -42%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 90% below the current price.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $651M | $491M | $233M | $145M | $109M | $132M | $198M | $175M | $164M | $155M | $134M |
| Net income | -$122M | -$26M | -$322M | -$111M | -$278M | -$180M | -$169M | -$146M | -$103M | -$60M | -$48M |
| Free cash flow | -$27M | — | — | -$281M | -$186M | -$20M | -$50M | -$58M | -$26M | $7M | -$5M |
| EPS (diluted) | $-1.29 | $-0.29 | $-4.08 | $-1.50 | $-4.37 | $-3.01 | $-3.56 | $-3.46 | $-2.54 | $-1.54 | $-1.29 |
| Net margin | -18.7% | -5.2% | -137.9% | -76.7% | -254.4% | -136.6% | -85.4% | -83.5% | -62.5% | -38.6% | -35.9% |
| ROIC | — | -11.2% | -65.3% | -50.6% | -56.1% | -27.9% | -34.7% | -31.5% | -12.0% | -12.6% | -13.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 14 analysts is $73.43, 45% above the current price; targets range from $62.00 to $86.00; the consensus rating is “Strong buy”; expected EPS is $0.53 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Travere Therapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 90% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Travere Therapeutics pay a dividend?
Not currently.
Is Travere Therapeutics a good stock to buy?
We do not give buy or sell advice. Travere Therapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.